Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
The trouble with TIGITs: How 'overenthusiasm' led to Big Pharma's risky $6B gamble
Purdue Pharma
Biotech
Amyloidosis biotech Attralus nabs $116M for clinical development
Attralus Therapeutics has scored $116 million to bring a handful of amyloidosis therapies into the clinic.
Emmy Lucas
Sep 8, 2021 3:28pm
Purdue subsidiary buys non-opioid pain prospect
Aug 11, 2021 8:20am
Ex-Purdue CEO Timney lands at amyloidosis biotech Attralus
May 11, 2021 11:05am
Former Merrimack CEO becomes new Yumanity chief—Chutes & Ladders
Jul 12, 2019 9:30am
Purdue hires Ducharme as CSO to aid expansion beyond opioids
Jul 3, 2019 10:35am
Eisai buys Purdue stake in insomnia drug as PDUFA date nears
May 1, 2019 9:28am
